Lowering of infarct growth correlated with clinically meaningful improvements in several functional stroke measures that evaluate a patient’s recovery TACOMA, Wash., Feb. 5, 2025 /PRNewswire/ — ...
The bolus thrombolytic agent tenecteplase narrowly failed to show noninferiority to alteplase in the TASTE clinical trial within 4.5 hours of symptom onset selected by perfusion imaging in patients ...
Please provide your email address to receive an email when new articles are posted on . The study examined 458 adults given IV tenecteplase or placebo 4.5 to 24 hours after stroke. At 90 days after ...
WILLOWBROOK, Ill., April 27, 2020 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, ...
Brain in stroke. Magnetic resonance imaging (MRI) scan of an axial section through the brain of an 80-year-old male patient following a stroke. A stroke, or cerebrovascular accident (CVA), is the ...
Tenecteplase shows no benefit over standard care for 90-day functional recovery in patients with minor ischemic stroke and disabling deficits.
The MarketWatch News Department was not involved in the creation of this content. LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ...
For acute ischemic stroke within 48 hours of onset, the novel sublingual combination of edaravone (Radicava) with dexborneol appeared to dramatically improve functional outcomes in the phase III TASTE ...
Please provide your email address to receive an email when new articles are posted on . The odds ratio of a worse modified Rankin score in the asymptomatic hemorrhagic infarction and subarachnoid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback